人VEGFR2蛋白, His Tag (MALS verified)

Human VEGF R2 / KDR Protein, His Tag (MALS verified)

分子别名（Synonym）

KDR, CD309, FLK1, VEGFR, VEGFR2

表达区间及表达系统（Source）

Human VEGF R2, His Tag (KDR-H5227) is expressed from human 293 cells (HEK293). It contains AA Ala 20 - Glu 764 (Accession # AAI31823.1).

Predicted N-terminus: Ala 20

蛋白结构（Molecular Characterization）

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 85.2 kDa. The protein migrates as 120-150 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素（Endotoxin）

Less than 1.0 EU per μg by the LAL method / rFC method.

纯度（Purity）

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

背景介绍

激酶插入结构域受体（KDR）亦称为CD309、FLK1、VEGFR、VEGFR2，是血管内皮生长因子受体（VEGFR）的亚型之一。VEGF受体是血管内皮生长因子（VEGF）的特异性受体，主要包含1、2、3三种亚型。该类受体具有由7个免疫球蛋白样结构域组成的胞外部分、单次跨膜区以及含有分裂酪氨酸激酶结构域的胞内部分。VEGF-A可与VEGFR-1（Flt-1）和VEGFR-2（KDR/Flk-1）结合。已知VEGFR-2几乎介导所有VEGF诱导的细胞应答反应；而VEGFR-1的功能虽尚未完全明确，但被认为可调节VEGFR-2的信号传导。此外，VEGFR-1可能作为假性/诱骗受体，通过隔离VEGF阻止其与VEGFR-2结合（这一功能在胚胎血管形成过程中尤为重要）。值得注意的是，VEGFR2在VEGF激活后能与HIV-1病毒外膜Tat蛋白相互作用，该机制似乎促进了卡波西肉瘤病灶中的血管生成。